| pubmed-article:20498647 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0079189 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0856825 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0663182 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0333348 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0666743 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:20498647 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:20498647 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:20498647 | pubmed:dateCreated | 2011-3-9 | lld:pubmed |
| pubmed-article:20498647 | pubmed:abstractText | Treatment options for steroid-refractory GVHD (SR-GVHD) are unsatisfactory and prognosis is poor. Inflammatory cytokines IL-2 and TNF-? are important mediators of GVHD and may be critical targets for therapy. We retrospectively reviewed our experience using combination anti-cytokine therapy of daclizumab and infliximab. Seventeen evaluable patients had a median age of 47 years (range 35-63). The conditioning regimen was myeloablative in 13 and non-myeloablative in 4 cases. GVHD occurred at a median of 49 days after transplant in 12 patients (range 21-231 days) and at a median of 46 days (range 25-119 days) after donor lymphocyte infusion in 5 patients. All patients had persistent or progressive GVHD despite 1-2?mg/kg/day of corticosteroids for a median of 7 days (range 2-26 days). They received a combination of daclizumab and infliximab for acute GVHD IBMTR severity index B (3), C (10) or D (4). Of the 17 patients analyzed, 47% responded to treatment, 24% had complete resolution of symptoms and 24% had partial responses. Survival was limited and all the patients died a median of 6.7 months (range 1.6-26) from transplant and 35 days from initiation of daclizumab/infliximab. This retrospective analysis suggests that combination anti-cytokine therapy with daclizumab/infliximab has significant activity in SR-GVHD, but outcomes remain poor. New methods to prevent and treat GVHD are urgently needed. | lld:pubmed |
| pubmed-article:20498647 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20498647 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20498647 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20498647 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20498647 | pubmed:issn | 1476-5365 | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:DavisJJ | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:SmithJJ | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:ReshefRR | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:FreyNN | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:TsaiDD | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:PerzSS | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:PorterD LDL | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:LugerS MSM | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:StadtmauerE... | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:GoldsteinS... | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:LorenAA | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:RagerAA | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:HexnerE OEO | lld:pubmed |
| pubmed-article:20498647 | pubmed:author | pubmed-author:VozniakMM | lld:pubmed |
| pubmed-article:20498647 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20498647 | pubmed:volume | 46 | lld:pubmed |
| pubmed-article:20498647 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20498647 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20498647 | pubmed:pagination | 430-5 | lld:pubmed |
| pubmed-article:20498647 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:meshHeading | pubmed-meshheading:20498647... | lld:pubmed |
| pubmed-article:20498647 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:20498647 | pubmed:articleTitle | Inflammatory cytokine inhibition with combination daclizumab and infliximab for steroid-refractory acute GVHD. | lld:pubmed |
| pubmed-article:20498647 | pubmed:affiliation | Division of Hematology-Oncology, Blood and Marrow Transplant Program, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA. alison.rager@uphs.upenn.edu | lld:pubmed |
| pubmed-article:20498647 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20498647 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
